Osoczowe stężenia frakcji adiponektyny u kobiet z chorobą Alzheimera

Abstract

Introduction Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disease. Typical features of AD include memory loss, social dysfunction and physical impairment. Although the pathological findings in the central nervous system are well established, the etiological factors are poorly known. Recent studies suggested the role of metabolic disturbances in the development of AD neurodegeneration. Adiponectin, an anti-inflammatory and metabolism regulating factor, was linked to AD. Aim The aim was to examine whether adiponectin fractions combined with insulin/insulin resistance-associated metabolic parameters correlate with AD progression. Material and methods The study comprised 98 women: 27 with moderate to severe AD, 31 with AD at early stage and 40 healthy controls, matched for age and BMI. To evaluate memory impairment, the MMSE was performed. Plasma total adiponectin and its high-, medium- and low molecular weights were measured with ELISA. Anthropometric, clinical and metabolic parameters were assessed. Correlations between adiponectin array and measured parameters were evaluated. Results In comparison to the controls, enhanced levels of total and medium molecular weight adiponectin characterized AD individuals. In AD, we found correlations between adiponectin array, and anthropometric and biochemical parameters. After adjustment to BMI, a significant increase of the total adiponectin and high- and medium molecular weight fractions was observed. A negative correlation between low molecular weight adiponectin and MMSE was found. Conclusions Our results indicate a possible link between adiponectin variations and AD. We hypothesize that changes in adiponectin profile observed in AD result from compensatory mechanism against neuropathological processes, as well as from adiponectin homeostasis impairment.

Assessing adipokines as potential biomarkers of dementia, Alzheimer's disease, and mild cognitive impairment: A systematic review and meta‐analysis

“…We included 24 studies published between 2009 and 2023. All of them presented results on blood (serum or plasma) adiponectin 45,47–50,52,53,59–61,65,67–79 . Additionally, two of them included CSF measurements of adiponectin.…”

“…All of them presented results on blood (serum or plasma) adiponectin. 45,[47][48][49][50]52,53,[59][60][61]65,[67][68][69][70][71][72][73][74][75][76][77][78][79] Additionally, two of them included CSF measurements of adiponectin. They included 6757 participants, and 3778 of them were women.…”

Assessing the blood concentration of new adipocytokines in patients with ischaemic stroke

“…Obesity, because of its coincidence with developing cardiovascular diseases, is perceived as an increasingly significant clinical problem. The role of adipose tissue and the mechanisms of action of proteins secreted by adipose tissue in the context of IS have not been fully explored [4][5][6].…”

The role of adipokines in the pathogenesis and course of selected respiratory diseases

“…Visceral adiposity is associated with decreased serum adiponectin levels, peripheral resistance to insulin, and an increased risk of cardio-metabolic complications [5]. Adiponectin was also linked with an anti-inflammatory, anti-oxidative, and metabolism regulating functions [6,7].…”